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Fig. 1. Transerve CT image of a female patient with CWR of breast cancer. 
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Abstract—This work explores different coupling 
configurations (direct contact, air and water coupling) between a 
single 915 MHz waveguide applicator and human tissue in the 
setting of chest wall recurrence (CWR) of breast cancer. The 
objective is to treat chest wall tumours with microwave 
hyperthermia, while avoiding hot spots in critical areas such as 
scars and ribs. The best coupling configuration was a customized 
24×29 cm water bolus developed by our team. It helps the 
applicator deliver an effective field size of 268 cm2 at 1 cm depth 
and a penetration depth of 2-3 cm. Water bolus thickness can be 
adjusted during treatment (0.5-4 cm) to shift hot spot locations 
and thus homogenize thermal dose delivered over a 60 min 
hyperthermia treatment. The virtual human chest model is easily 
customized so it can be used as a tool for treatment planning and 
quality assurance testing of microwave applicator configurations. 
Index Terms—microwave antenna, chest wall recurrence, 
treatment planning, breast cancer, hyperthermia. 
I.  INTRODUCTION 
The efficacy of adding superficial hyperthermia to 
radiotherapy for chest wall recurrence (CWR) of breast cancer 
has previously been established in randomized trials [1, 2]. 
However, a definite consensus towards appropriate treatment 
delivery has not been achieved and existing clinical guidelines 
are currently being redefined [3, 4]. This paper reviews the 
critical elements in superficial hyperthermia treatments for 
CWR, and presents a virtual human chest model to be used as 
a tool for treatment planning and quality assurance testing of 
different microwave applicator configurations.  
The treatment planning of superficial microwave 
hyperthermia treatments considers three main components: 
applicator, coupling between applicator and tissue, and patient 
disease. Typical microwave applicators for these treatments 
operate either at 434 MHz (Europe) or 915 MHz (USA). 
Single and array applicators have been explored [5-7], but for 
clinical practice in the USA, only single waveguide applicators 
have been approved. The most common coupling mechanism 
is a water bolus. It consists of a flexible plastic bag filled with 
circulating deionized water at a controlled temperature. It plays 
a critical role since it homogenizes the radiation field and cools 
the skin, diffusing superficial hot spots and allowing minor 
adjustment of penetration depth. This becomes especially 
useful for low perfusion tissues such as scars that are typical in 
CWR and have reduced ability to dissipate heat. Several 
parameters of the coupling bolus must be considered: dielectric 
properties, temperature, flow rate, shape, size, and thickness 
[3, 8, 9]. Finally, one must also account for human anatomy, 
tissue thermophysical properties [10-14] including dynamic 
temperature dependent blood perfusion [15, 16], and most 
importantly patient tolerance.  
In this work, three computational models are assessed to 
evaluate different aspects of a superficial hyperthermia 
treatment. The first replicates a muscle-like homogenous 
phantom used to validate the computational model (model 1). 
The second is similar to the first but with actual human muscle 
properties (model 2). Finally, a “virtual human” test model is 
developed for treatment planning, which includes typical scars 
and tumours of CWR with different properties (model 3). In 
this model, the target temperature for hyperthermia cancer 
treatment is defined in the range 40-45°C [7]. 
II. METHODS 
A. Experimental setup 
The applicator analysed in this study is a rectangular slab-
loaded waveguide with dimensions 17.4×23.6×19.6 cm 
(MA120, BSD Medical Corporation, Salt Lake City, Utah). 
The radiated fields produced by the antenna were measured 
with a miniature three-axis electric field probe  with 1 mm step 
size (Model 8021 B SAR Probe, Narda Corp, Hauppauge, NY) 
in a tank containing a liquid muscle-like phantom. The probe 
provides linearized output voltage directly proportional to the 










specific absorption rate SAR = σE2/2ρ, where σ is the electrical 
conductivity and ρ the density of the phantom, respectively. 
This fluid phantom is a standard mixture of ethylene glycol 
and saline which matches the dielectric properties of muscle at 
915 MHz: 70% laboratory grade ethylene glycol, 28% distilled 
water and 2% non-iodized table salt (properties on Table I).  
B. Computational model 
All models include the complete structure of the slab-
loaded waveguide applicator, using σ = 4.75 for the packed 
crystalline sodium chloride chambers against the sidewalls. 
The load dimensions of models 1 (phantom) and 2 (muscle) 
are 35×44×13 cm and the thermophysical properties are 
presented in Table I. Model 3 consists of a mixture of tumour, 
skin, blood, necrotic tissue as well as adipose and 
fibroconnective tissues typical of CWR (Fig. 1). The 
thermophysical and biological properties of this heterogeneous 
tissue vary by several orders of magnitude [11, 14, 17].  Fig. 2 
shows the multi-layer model 3, which includes 1.5 mm skin, 8 
mm fat, 1 cm muscle, 9 cm lung and 3 ribs (bone) located 1 
mm above the lung in the muscle region. This model also 
includes two scars (0.35×10×1 cm) running perpendicular and 
parallel to the electric field (E-field) and three distinct tumours. 
Many different tumour geometries can be considered in CWR, 
including carcinomas, melanomas, and even some lymphomas. 
Many are diffuse disease involving skin while others are 
discrete nodules. Therefore, we account for one 
adenocarcinoma as seen in Fig. 1 (cylinder with 1.5 cm radius 
and height) and two elliptically shaped chest wall tumours 
(3x5x1.5 cm) – Tumour L and Tumour H with low and high 
blood perfusion, respectively. The thermophysical properties 
for all tissue regions are given in Table I. 
The E-field and temperature are calculated in COMSOL 
Multiphysics (COMSOL, Palo Alto, CA) – a finite element 
software – to solve the combined bioheat transfer equation and 
Maxwell equations [17]. The bioheat equation consists of an 
extended version of the classic heat equation with a heat sink 
due to blood perfusion (ωb), an internal heat source due to 
metabolism (Qm) and an external heat source due to absorption 
of microwave energy derived from the applicator (ρSAR). The 
electro-thermal model is meshed with manual settings, where 
the maximum mesh element size of each object is λair/sqrt(ε) 
with λair the wavelength in air and ε  the dielectric constant of 
the meshed object. The resulting model consists of 
approximately 1×106 tetrahedral elements. All simulations are 
performed for an operating frequency of 915 MHz. The 
cooling bolus is embodied in a Robin boundary condition with 
variable Tbolus and fixed hbolus = 85 W/m2/K [3]. In the top and 
lateral surfaces, we impose a similar boundary condition due to 
air cooling with Tair = 25°C and hair = 5 W/m2/K. At the 




Fig. 2. Model 3 – virtual human chest model with 1.5 mm skin, 8 mm fat, 
2 cm muscle, and 10 cm lung thicknesses. Lateral dimensions are 36×44 cm. 
Waveguide aperture dimensions are 17.4×23.6 cm. Tumor L and Tumour H 
correspond to low and high blood perfusion tumours, respectively. 
 
TABLE I.  THERMAL, BIOLOGICAL AND DIECTRIC PROPERTIES OF HUMAN TISSUES AND PHANTOM MATERIALS. 






















Skin (skin wet) 1109 [10] 3391 [10] 0.37 [10] 0.97×F(T) [10] 1827 [10] 9.2 [15] 10 [15] 44 [15] 46.0 [13] 0.85 [13] 
Subcutaneous fat 911 [10] 2348 [10] 0.21 [10] 0.52×F(T) [10] 461 [10] 1.0 [15] 12 [15] 45 [15] 5.5 [13] 0.05 [13] 
Muscle 1090 [10] 3421 [10] 0.49 [10] 0.75×F(T) [10] 1052 [10] 7.9 [15] 12 [15] 45 [15] 55.0 [13] 0.95 [13] 
Lung 722 [10] 3886 [10] 0.39 [10] 5.06×F(T) [10] 4483 [10] 7.9 [15] 12 [15] 45 [15] 36.7 [13] 0.66 [13] 
Rib 1543 [10] 1793 [10] 0.32 [10] 0.48×F(T) [10] 421 [10] 1.0 [15] 12 [15] 45 [15] 16.6 [13] 0.24 [13] 
Scar (skin dry) 1109 [10] 3391 [10] 0.37 [10] - - - - - 41.3 [13] 0.87 [13] 
Blood 1050 [10] 3617 [10] 0.52 [10] - - - - - 61.3 [13] 1.54 [13] 
Low ωb tumour 1090 [10] 3421 [10] 0.49 [10] 0.58×F(T) [12] 1225 [12] 2.0 [16] 12 [16] 43 [16] 51.3 [14] 0.89 [14] 
High ωb tumour  1090 [10] 3421 [10] 0.49 [10] 1.91×F(T) [12] 2267[12] 2.0 [16] 12 [16] 43 [16] 56.3 [14] 0.97 [14] 
Adenocarcinoma 1090 [10] 3421 [10] 0.49 [10] 7.63×F(T) [11] 3754 [12] 2.0 [16] 12 [16] 43 [16] 60.0 [14] 1.07 [14] 
Muscle phantom 1097 3083 0.31 - - - - - 46a 1.26a 
De-ionized water  992 4176 0.63 - - - - - 79a 0.18a 
ameasured. 
 Finally, we account for thermoregulation. Blood perfusion, 
in particular, plays a critical role in hyperthermia treatments 
since it is a dynamic heat sink that varies with temperature [15, 
16]. To account for this thermoregulatory effect, we included a 
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where ω1 and s are curve fitting parameters derived from 
experimental data; and Tcr is a critical temperature that is 
tissue-specific (Table I).  
C. Parametric studies 
SAR patterns of the MA120 applicator were measured and 
simulated at a depth of 5 mm in model 1 for four different 
coupling configurations: direct contact; 3 cm air coupling and 
no water bolus; BSD water bolus (19.4×27.6×3 cm), which 
integrated in a teflon frame; and a custom water bolus bag  
(24×29×3 cm). Water flow was approximately 3.6 l/min as 
controlled with the BSD 500 water conditioning system (BSD 
Medical Corporation, Salt Lake City, Utah). For 
characterization purposes, we chose to determine the effective 
field size (EFS) that is the area of the 50% SAR contours 
measured at 1 cm depth, and the penetration depth (PD) that is 
the distance below 1 cm at which SAR falls to 50% of that at 1 
cm [5]. In model 2, the EFS and PD were determined for 
several different thickness of water and air coupling: 5, 13, 20, 
30 and 40 mm.  
III. RESULTS 
A. Experimental validation of computational model 
The experimental SAR results were measured and 
normalized in a  plane 5 mm deep in the phantom. Simulations 
of all configurations in the matching model 1 are in good 
agreement  with the measured SAR patterns. The 3 cm air gap 
configuration is shown in Fig. 3 as an example.  
In Fig. 4, simulations of both direct contact and air 
coupling configurations show a Gaussian-like pattern, with 
50% SAR areas of 18×18 cm2 and 13×22 cm2, respectively. 
The use of a water bolus improves coupling between applicator 
and tissue. Both water boluses present a similar field size at 5 
mm depth of approximately 16×16 cm2. However, the use of a 
larger water bolus bag produces a more homogennous SAR 
pattern that is desirable for superficial hyperthermia treatment. 
B. Characterization of different applicator configurations 
The penetration depth and effective field size at 1 cm depth 
in model 2 are presented in Table II. The average PD is 2 cm 
and it is higher for water coupling due to improved impedance 
matching. Increasing the separation between applicator and 
muscle load decreases EFS for both air and water coupling. 
However, for water boluses thicker than 1 cm there is a non-
linear behaviour, explained by SAR perturbations arising due 
to resonance inside the bolus [8]. Although the EFS of air 
coupling is higher, its centrally peaked SAR pattern is less 
desirable for treatment of large area CWR (Fig. 4).  
C. Heating of virtual human chest wall test phantom 
In Fig. 5, we present the range of volume (dark green) and 
surface (light green) temperatures as well as SAR distribution 
(blue) for each tissue region. The following setup is typical in 
our clinic: bolus temperature = 42°C; bolus thickness = 13 mm 
(Fig. 5A) or 30 mm (Fig. 5B); input power = 160 W. The 
advantage of presenting both temperature and SAR together is 
that it emphasizes the impact on temperature increase of the 
quite different power deposition and thermal properties of the 
various tissue regions. For instance, the two tumours that differ 
only in blood perfusion absorb a similar SAR range, but 
 
Fig. 3. Experimental (A) and simulated (B) SAR pattern at 5 mm depth in 
model 1 for 3 cm air coupling between applicator and liquid muscle phantom.
 
Direct contact 3cm air BSD bolus 19.4×27.6×3 cm 
Custom bolus
 24×29×3 cm 
1 
0.5  
Fig. 4. Normalized SAR pattern at 5 mm depth in model 1 for four 
applicator configurations. The external white frame corresponds to the 
waveguide boundaries: 17.4×23.6 cm. 
TABLE II.  PENETRATION DEPTH AND EFFECTIVE FIELD SIZE FOR 
SEVERAL WATER AND AIR SEPARATIONS BETWEEN APPLICATOR AND SKIN. 
Thickness 
(mm) 
PD (cm) EFS (cm2) 
Water Air Water Air 
Direct contact 2.3 311 
5 2.1 2.0 293 401 
9 2.0 1.8 283 371 
13 2.0 1.9 281 344 
20 2.1 1.9 266 305 
30 1.9 1.9 245 287 
40 2.0 1.9 240 278 
BSD bolus (30mm) 1.6 - 264 - 
have a 4°C difference in maximum temperature. The 
adenocarcinoma absorbs even more energy (higher SAR) due 
to possible resonance effects within its 1.5 cm structure.  
However, this did not produce tumour temperatures in the 
desired 40-45°C range (shaded) due to the very high perfusion 
(7.63 kg/s/m3) which represents a worst case of tissue 
properties [11]. Nonetheless, the two large tumours (L and H) 
were the primary targets for the treatment since they are 
centered in the applicator. These tumours achieve a T90 of 
41.5°C (tumour L) and 40.3°C (tumour H) for 13 mm bolus 
thickness, meaning that 90% of the tumour exceeds the T90 
temperature [17]. The remaining 10% of tumor absorbs less 
energy as the SAR pattern falls off rapidly at the tumor edges.  
In Fig. 5, separate reporting of surface temperate range 
(light green) enhances understanding of deeper temperatures in 
the same tissue regions. In the clinic, eight measurements are 
typically collected per treatment. Due to the cooling effect of 
the bolus and higher power deposition at the surface, the 
temperature differentials are significant. They range from 1°C 
(adenocarcinoma) to 4.3°C (tumour H) in terms of surface 
temperature, but can reach 7°C (tumour L) in terms of volume 
temperature differential. 
  
The effect of constructive interference due to reflections at 
the sharply contrasting rib/muscle dielectric interfaces can be 
observed in Fig. 6. In this model, SAR from the 915 MHz field 
does not cause overheating of surface tissues since the ribs are 
2.5 cm deep. For mastectomy patients that often have less than 
1-1.5 cm tissue overlying the ribs, hot spots may result above 
and between the ribs.  
IV. DISCUSSION 
In this work, we validate a new treatment planning model 
for the BSD MA120 waveguide applicator and characterize 
four applicator/bolus setups for superficial CWR treatments. 
Current tools allow segmentation of patient-specific 
anatomical models [18], but these are time consuming and not 
yet practical for routine planning. We use a virtual human 
chest wall model as a tool for quick assessment of different 
treatment configurations. The model includes all structures 
typical of chest wall recurrence, and is easily customized.  
Although this study addresses a single applicator, it 
illuminates several mechanisms available to adjust temperature 
distribution under a microwave applicator. The air coupling 
was implemented since it is relevant in some extreme cases, 
where patients present open wounds with active bleeding and 
are intolerant to pressure. However, the use of water bolus is 
always preferable in order to control skin temperature. 
In Fig. 5, temperature and SAR distributions are presented 
for different bolus thicknesses. By increasing the thickness 
from 13 mm to 30 mm, the maximum temperatures of healthy 
tissues decrease up to 0.7 °C while maintaining tumours T90 
within the range 40-45°C. In practice, when placed on a 
contoured chest, the bolus thickness can reach 4-5 cm at its 
borders, while in the centre it may be less than 1 cm thick. 
Clearly, variations in bolus thickness contribute to hot spots, 
but those hot spots can be shifted around under the aperture as 
shown in Fig. 4 to homogenize thermal dose delivered over a 
60 min treatment.  
The development of hot spots is unavoidable in HT 
treatment, and in extreme cases might lead to pain and blisters.  
Overheating may occur at bone/muscle and fat/muscle 
interfaces, and in poorly perfused tissues such as scars, grafts 
and the interior of necrotic tumours. The scars of model 3, 
which run parallel and perpendicular to the electric field, 
demonstrate that power absorption and tissue temperature are 
very different, even though both scars are located within the 
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Fig. 5. Temperature and SAR distribution for all tissues in model 3 with  
Tbolus = 42°C, bolus thickness = 13 mm (A) and 30 mm (B);  antenna power 
= 160 W (Tumor H = tumor with high blood perfusion; Tumor L =tumor 
with low blood perfusion; Scar PL = parallel scar; Scar PR = perpendicular 
scar). Muscle, skin, fat and rib temperatures are taken from the effective 
heating volumes limited by the waveguide boundaries (17.4×23.6 cm). T90 
is presented above the graph.  
50% SAR contour. In fact, parallel orientation produces 
preferential heating of scar tissue, suggesting rotation of the 
applicator to avoid preferential accumulation of heat in the 
scars.   
In this work we accounted for tissue-specific temperature 
dependent perfusion. Without this effect, only 60 W were 
required to heat the model 3 tumour target regions into the 
desired 40-45°C range. However, after accounting for 
thermoregulation, the heat dissipation increased and more 
power was required. The power used to obtain the distributions 
in Figs. 5 and 6 was 160 W, which agrees with the 120-180 W 
range used clinically for the MA120.  
Finally, penetration depth is a parameter that has different 
definitions in the literature. If we apply the definition 
traditionally used in hyperthermia [5], the penetration depth is 
about 2 cm for different applicator configurations (Table II). 
However, others have defined PD as the depth at which the 
SAR becomes 1/e2 of its value at the surface. In this case the 
effective PD is 3 cm, which is consistent with 3 cm deep 
tissues (lung) reaching 40°C (Fig. 5). Ultimately, the 
temperature and consequently thermal dose distribution is what 
is most relevant clinically [7, 17]. The relevance of 
temperature is sometimes embodied in T90, which is useful to 
quantify the temperature distribution. However, thermal 
modeling assessment of complete temperature ranges for all 
tissues is a valuable tool to predict the location of hot spots and 
thus improve treatment quality.  
In summary, the virtual human chest wall model facilitates 
instructive treatment planning that can be easily adjusted to 
model individual anatomies, such as different thicknesses and 
depths of fat, scars, tumours and ribs. In our clinic, the 
majority of patients present disease dispersed within the top 1-
2 cm. Deeper tumours can also be heated by increasing input 
power and decreasing the bolus temperature [3].  
V. CONCLUSIONS 
A simplified 3D computer model was developed for the 
study of superficial hyperthermia treatments with a single 
microwave waveguide applicator. All clinically relevant 
structures were included in the model. Although single 
waveguide applicators are fairly simple, there are several 
parameters that can be adjusted to minimize hot spots that 
cause pain and blisters. While heating pattern peaks are 
unavoidable, they can be shifted during treatment by varying 
bolus temperature and thickness. The custom water bolus bag 
demonstrated better performance than the teflon frame bolus 
supplied with the applicator. The proposed temperature and 
SAR range analysis facilitates rapid global assessment of 
CWR treatment quality. The presented simplified computer 
model can then be integrated in routine treatment planning into 
quality assurance (QA) practice for improved therapy in the 
clinic. 
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